Skip to main content
. 2024 Feb 2;39(6):350–360. doi: 10.1097/YIC.0000000000000536

Table 4.

Multivariate analysis assessing association between variables and the likelihood of experiencing a clinically significant benefit in GAD-7 at 12 months

Variable n OR (95% CI) P-value
Age
 <30 28 1
 31–40 41 2.674 (0.621–11.506) 0.187
 41–50 23 6.721 (1.334–33.858) 0.021*
 51–60 12 1.852 (0.280–12.240) 0.523
 60+ 5 1.156 (0.057–23.424) 0.925
Gender
 Male 67 1
 Female 42 1.568 (0.467–5.261) 0.466
BMI (kg/m2)
 <25 44 1
 25–30 37 0.435 (0.109–1.731) 0.237
 30–35 12 1.662 (0.280–9.868) 0.576
 >35 16 3.911 (0.845–18.108) 0.081
Prior cannabis usage status
 Current user 53 1
 Ex-user 29 1.031 (0.299–3.551) 0.961
 Never used 27 0.958 (0.196–4.685) 0.958
CBMP prescription
 Oils 34 1
 Dried flower 48 21.964 (0.752–641.491) 0.073
 Both 27 11.563 (0.442–302.527) 0.142
CBD contents in CBMP
 No CBD 13 1
 ≤ Median dose of cohort (≤31.25 mg/day) 41 4.583 (0.625–33.605) 0.134
 > Median dose of cohort (>31.25 mg/day) 55 3.248 (0.417–25.316) 0.261
THC contents in CBMP
 ≤ Median dose of cohort (≤100.00 mg/day) 40 1
 > Median dose of cohort (>100.00 mg/day) 69 0.311 (0.021–4.680) 0.398
Baseline GAD-7 score
 0–9 (minimal or mild) 23 1
 10–14 (moderate) 30 4.537 (0.735–28.004) 0.103
 15–21 (severe) 56 16.018 (2.157–118.963) 0.007**
Baseline SQS score
 ≤ 3 (sleep impaired) 61 1
 > 3 (non-sleep impaired) 48 0.991 (0.320–3.066) 0.987

Significant differences are denoted by asterisks (*P < 0.050,**P = 0.010, and ***P < 0.001).